Targeting OAT3 for Therapeutic Benefits in Obesity and Related Diseases

Target Name: SLC22A8

NCBI ID: G9376

SLC22A8

Targeting OAT3 for Therapeutic Benefits in Obesity and Related Diseases

SLC22A8 (OAT3) is a gene that encodes a protein known as OAT3, which is a water-exciting transthyretin. OAT3 is a member of the transthyretin family, which includes proteins that are involved in the transport of lipids across cell membranes. In particular, OAT3 is involved in the transport of triacylglycerols (triglycerides) across cell membranes, which are a common form of dietary fat that can contribute to various health conditions, including obesity and cardiovascular disease.

The SLC22A8 gene has been identified as a potential drug target or biomarker for various diseases, including obesity, type 2 diabetes, and cardiovascular disease. This is because OAT3 is involved in the transport of lipids across cell membranes, and changes in the levels of OAT3 or its activity have been observed in various diseases. For example, studies have shown that individuals with obesity have lower levels of OAT3 in their adipose tissue compared to individuals with normal weight. Additionally, OAT3 has been shown to be involved in the regulation of lipid metabolism and has been implicated in the development and progression of various cardiovascular diseases, including obesity and type 2 diabetes.

One of the potential benefits of targeting OAT3 with drugs is that it can help to reduce the levels of triglycerides in the body and improve lipid metabolism. This can be especially beneficial in individuals with obesity, as obesity is a major risk factor for various cardiovascular and metabolic diseases. In addition, targeting OAT3 with drugs may also have potential benefits in individuals with type 2 diabetes, as OAT3 has been shown to be involved in the regulation of insulin sensitivity and glucose metabolism.

Another potential benefit of targeting OAT3 with drugs is that it may help to improve the sensitivity of tissues to insulin. This can be especially beneficial in individuals with type 2 diabetes, as insulin sensitivity is an important factor in the development and progression of the disease. In addition, targeting OAT3 with drugs may also have potential benefits in individuals with unexplained hyperlipidemia, a condition in which individuals have high levels of triglycerides in their blood despite normal levels of cholesterol.

Targeting OAT3 with drugs may also have potential benefits in individuals with certain genetic mutations, such as the SLC22A8 gene. Studies have shown that individuals with certain genetic mutations, including those that are associated with obesity and cardiovascular disease, have lower levels of OAT3 in their adipose tissue compared to individuals with normal weight. Therefore, targeting OAT3 with drugs may be a promising approach for treating individuals with these genetic mutations.

In conclusion, SLC22A8 (OAT3) is a gene that encodes a protein involved in the transport of triglycerides across cell membranes. The SLC22A8 gene has been identified as a potential drug target or biomarker for various diseases, including obesity, type 2 diabetes, and cardiovascular disease. Targeting OAT3 with drugs may have potential benefits in reducing the levels of triglycerides, improving lipid metabolism, and improving insulin sensitivity in various tissues. Additionally, targeting OAT3 with drugs may also have potential benefits in individuals with certain genetic mutations that are associated with obesity and cardiovascular disease. Further research is needed to fully understand the potential benefits and risks of targeting OAT3 with drugs.

Protein Name: Solute Carrier Family 22 Member 8

Functions: Functions as an organic anion/dicarboxylate exchanger that couples organic anion uptake indirectly to the sodium gradient (PubMed:14586168, PubMed:15644426, PubMed:15846473, PubMed:16455804, PubMed:31553721). Transports organic anions such as estrone 3-sulfate (E1S) and urate in exchange for dicarboxylates such as glutarate or ketoglutarate (2-oxoglutarate) (PubMed:14586168, PubMed:15846473, PubMed:15864504). Plays an important role in the excretion of endogenous and exogenous organic anions, especially from the kidney and the brain (PubMed:14586168, PubMed:15846473, PubMed:11306713). Responsible for the transport of prostaglandin E2 (PGE2) and prostaglandin F2(alpha) (PGF2(alpha)) in the basolateral side of the renal tubule (PubMed:11907186). May be involved in the basolateral transport of steviol, a metabolite of the popular sugar substitute stevioside (PubMed:15644426). May participate in the detoxification/ renal excretion of drugs and xenobiotics, such as the histamine H(2)-receptor antagonists fexofenadine and cimetidine, the antibiotic benzylpenicillin (PCG), the anionic herbicide 2,4-dichloro-phenoxyacetate (2,4-D), the diagnostic agent p-aminohippurate (PAH), the antiviral acyclovir (ACV), and the mycotoxin ochratoxin (OTA), by transporting these exogenous organic anions across the cell membrane in exchange for dicarboxylates such as 2-oxoglutarate (PubMed:15846473, PubMed:16455804). Contributes to the renal uptake of potent uremic toxins (indoxyl sulfate (IS) and 3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF)), pravastatin, PCG, E1S and dehydroepiandrosterone sulfate (DHEAS), and is partly involved in the renal uptake of temocaprilat (an angiotensin-converting enzyme (ACE) inhibitor) (By similarity). May contribute to the release of cortisol in the adrenals (PubMed:15864504). Involved in one of the detoxification systems on the choroid plexus (CP), removes substrates such as E1S or taurocholate (TC), PCG, 2,4-D and PAH, from the cerebrospinal fluid (CSF) to the blood for eventual excretion in urine and bile (By similarity). Also contributes to the uptake of several other organic compounds such as the prostanoids prostaglandin E(2) and prostaglandin F(2-alpha), L-carnitine, and the therapeutic drugs allopurinol, 6-mercaptopurine (6-MP) and 5-fluorouracil (5-FU) (By similarity). Mediates the transport of PAH, PCG, and the statins pravastatin and pitavastatin, from the cerebrum into the blood circulation across the blood-brain barrier (BBB). In summary, plays a role in the efflux of drugs and xenobiotics, helping reduce their undesired toxicological effects on the body (By similarity)

The "SLC22A8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC22A8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets